论文部分内容阅读
目的:观察促红细胞生成素(EPO)对急性心肌梗死患者经皮冠状动脉介入治疗(PCI)术后再灌注性心律失常的影响。方法:选取急性ST段抬高型心肌梗死且成功行PCI的患者120例,将其随机分为EPO 100 U/kg组、EPO 1 000 U/kg组及对照组,每组40例。EPO 100 U/kg组和EPO 1 000 U/kg组在PCI术前分别给予100 U/kg和1 000U/kg的EPO,对照组给予0.9%氯化钠溶液,观察PCI术后再灌注性心律失常发生情况,记录随访期间的主要不良心脏事件(MACE)及EPO相关不良反应发生情况。结果:共74例出现再灌注性心律失常(63.33%)。EPO 1 000 U/kg组房性期前收缩、心房颤动、室性期前收缩、室性心动过速、总心律失常发生率及室性心律失常评分均低于对照组(均P<0.05);EPO 100U/kg组房性期前收缩、心房颤动、室性期前收缩发生率低于对照组(均P<0.05)。3组患者随访6个月后不良反应发生无统计学差异。结论:急性心肌梗死患者PCI术前给予EPO对再灌注性心律失常具有一定缓解作用。
Objective: To observe the effect of erythropoietin (EPO) on reperfusion arrhythmia after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction. Methods: A total of 120 patients with acute ST-segment elevation myocardial infarction (PCI) were enrolled in this study. They were randomly divided into EPO 100 U / kg group, EPO 1000 U / kg group and control group, 40 cases in each group. EPO 100 U / kg group and EPO 1 000 U / kg group were given 100 U / kg and 1 000 U / kg of EPO before PCI, while 0.9% sodium chloride solution was given as control group. Reperfusion rhythm The incidence of abnormalities, major adverse cardiac events (MACE) and EPO-related adverse events during follow-up were recorded. Results: A total of 74 cases of reperfusion arrhythmia (63.33%). EPO 1 000 U / kg group atrial contraction, atrial fibrillation, ventricular premature ventricular contraction, ventricular tachycardia, total arrhythmia incidence and ventricular arrhythmia scores were lower than the control group (P <0.05) ; EPO 100U / kg group atrial contraction, atrial fibrillation, ventricular premature contraction was lower than the control group (P <0.05). There was no significant difference in adverse reactions between the 3 groups after 6 months of follow-up. Conclusion: EPO administration before PCI in patients with acute myocardial infarction can relieve reperfusion arrhythmia.